|
Oct 1
|
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
|
|
Sep 3
|
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 30
|
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
|
|
Aug 28
|
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
|
|
Jun 25
|
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
|
|
Jun 17
|
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
|
|
Jun 11
|
Sidoti Events, LLC's Virtual June Small-Cap Conference
|
|
Jun 6
|
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 5
|
Atossa to Present at the Sidoti Small-Cap Investor Conference
|
|
May 15
|
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
|
|
May 13
|
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
|
|
Apr 29
|
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
|
|
Apr 29
|
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
|
|
Apr 15
|
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
|
|
Apr 11
|
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
|
|
Apr 9
|
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
|
|
Apr 1
|
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
|
|
Mar 19
|
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
|
|
Mar 18
|
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
|